Cargando…

Evidence for non-neutralizing autoantibodies against IL-10 signalling components in patients with inflammatory bowel disease

BACKGROUND: Inflammatory bowel disease constitutes a heterogeneous group of conditions, whose aetiology is only partly understood. The prevailing hypothesis on its pathogenesis is that IBD is the result of an inadequate immune response to the resident bacterial flora of the intestine. An autoimmune...

Descripción completa

Detalles Bibliográficos
Autores principales:	Frede, Natalie, Glocker, Erik-Oliver, Wanders, Jennifer, Engelhardt, Karin R, Kreisel, Wolfgang, Ruemmele, Frank M, Grimbacher, Bodo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3942769/ https://www.ncbi.nlm.nih.gov/pubmed/24581234 http://dx.doi.org/10.1186/1471-2172-15-10

Ejemplares similares

Autoantibodies against BAFF, APRIL or IL21 - an alternative pathogenesis for antibody-deficiencies?
por: Pott, Marian-Christopher, et al.
Publicado: (2017)

Early-onset inflammatory bowel disease caused by mutant IL10 receptor
por: Glocker, E O, et al.
Publicado: (2010)

An update on the hyper-IgE syndromes
por: Yong, Patrick FK, et al.
Publicado: (2012)

IL-10 and IL-10 Receptor Mutations in Very Early Onset Inflammatory Bowel Disease
por: Zhu, Lei, et al.
Publicado: (2017)

Immune checkpoint deficiencies and autoimmune lymphoproliferative syndromes
por: Gámez-Díaz, Laura, et al.
Publicado: (2021)

Neutralizing Autoantibodies to Type I IFNs in >10% of Patients with Severe COVID-19 Pneumonia Hospitalized in Madrid, Spain
por: Troya, Jesús, et al.
Publicado: (2021)

Current concepts in pediatric inflammatory bowel disease; IL10/IL10R colitis as a model disease
por: Almana, Yousef, et al.
Publicado: (2019)

A polymorphism in the IL-10 promoter affects autoantibody production and subsequent joint destruction in rheumatoid arthritis
por: van Gaalen, FA, et al.
Publicado: (2003)

Bowel Histology of CVID Patients Reveals Distinct Patterns of Mucosal Inflammation
por: van Schewick, Cornelia M., et al.
Publicado: (2021)

Neutralization and clearance of GM-CSF by autoantibodies in pulmonary alveolar proteinosis
por: Piccoli, Luca, et al.
Publicado: (2015)

14 Years after Discovery: Clinical Follow-up on 15 Patients with Inducible Co-Stimulator Deficiency
por: Schepp, Johanna, et al.
Publicado: (2017)

Elevated IgA and IL-10 levels in very-early-onset inflammatory bowel disease secondary to IL-10 receptor deficiency
por: Sandy, Natascha Silva, et al.
Publicado: (2021)

Autoantibodies Neutralizing Type I IFNs in the Bronchoalveolar Lavage of at Least 10% of Patients During Life-Threatening COVID-19 Pneumonia
por: Philippot, Quentin, et al.
Publicado: (2023)

DOCK8 deficiency in six Iranian patients
por: Saghafi, Shiva, et al.
Publicado: (2016)

Low Lymphocytes and IFN-Neutralizing Autoantibodies as Biomarkers of COVID-19 Mortality
por: Troya, Jesús, et al.
Publicado: (2022)

Anti-GM-CSF Neutralizing Autoantibodies in Colombian Patients with Disseminated Cryptococcosis
por: Arango-Franco, Carlos A., et al.
Publicado: (2023)

The Relationship of Cytokines IL-13 and IL-17 with Autoantibodies Profile in Early Rheumatoid Arthritis
por: Siloşi, Isabela, et al.
Publicado: (2016)

Inflammatory arthritis associated with inflammatory bowel disease in children
por: Desgranges, M, et al.
Publicado: (2008)

IL‐6‐specific autoantibodies among APECED and thymoma patients
por: Kärner, Jaanika, et al.
Publicado: (2016)

IL-10: A possible immunobiological component of positive mental health in refugees
por: Keaton, Sarah A., et al.
Publicado: (2021)

Functional neutralization of anti-IFN-γ autoantibody in patients with nontuberculous mycobacteria infection
por: Krisnawati, Dyah Ika, et al.
Publicado: (2019)

Neutralizing Anti-interferon-γ Autoantibodies: an Ameliorating Factor in COVID-19 Infection?
por: Kacar, Mark, et al.
Publicado: (2021)

Neutralizing Autoantibodies to Type I Interferons in COVID-19 Convalescent Donor Plasma
por: Vazquez, Sara E., et al.
Publicado: (2021)

Neutralizing Type I Interferon Autoantibodies in Japanese Patients With Severe COVID-19
por: Eto, Shohei, et al.
Publicado: (2022)

Neutralizing Type I Interferon Autoantibodies in Japanese Patients with Severe COVID-19
por: Eto, Shohei, et al.
Publicado: (2022)

Evaluation of novel serological markers and autoantibodies in dogs with inflammatory bowel disease
por: Estruch, Juan J., et al.
Publicado: (2020)

“Immune TOR-opathies,” a Novel Disease Entity in Clinical Immunology
por: Jung, Sophie, et al.
Publicado: (2018)

Pre-existing Autoantibodies Neutralizing High Concentrations of Type I Interferons in Almost 10% of COVID-19 Patients Admitted to Intensive Care in Barcelona
por: Solanich, Xavier, et al.
Publicado: (2021)

IL-1β–dependent extravasation of preexisting lung-restricted autoantibodies during lung transplantation activates complement and mediates primary graft dysfunction
por: Yang, Wenbin, et al.
Publicado: (2022)

Deconvolution of monocyte responses in inflammatory bowel disease reveals an IL-1 cytokine network that regulates IL-23 in genetic and acquired IL-10 resistance
por: Aschenbrenner, Dominik, et al.
Publicado: (2021)

Identification and characterization of IL-10/IFN-γ–producing effector-like T cells with regulatory function in human blood
por: Häringer, Barbara, et al.
Publicado: (2009)

Anti-IL6 Autoantibodies in an Infant With CRP-Less Septic Shock
por: Bloomfield, Marketa, et al.
Publicado: (2019)

A biallelic mutation in IL6ST encoding the GP130 co-receptor causes immunodeficiency and craniosynostosis
por: Schwerd, Tobias, et al.
Publicado: (2017)

JAKs and STATs from a Clinical Perspective: Loss-of-Function Mutations, Gain-of-Function Mutations, and Their Multidimensional Consequences
por: Ott, Nils, et al.
Publicado: (2023)

Treatment of Infantile Inflammatory Bowel Disease and Autoimmunity by Allogeneic Stem Cell Transplantation in LPS-Responsive Beige-Like Anchor Deficiency
por: Bakhtiar, Shahrzad, et al.
Publicado: (2017)

Autoantibodies directed to novel components of the PM/Scl complex, the human exosome
por: Brouwer, Rick, et al.
Publicado: (2002)

Neutralizing GM-CSF autoantibodies in pulmonary alveolar proteinosis, cryptococcal meningitis and severe nocardiosis
por: Salvator, Hélène, et al.
Publicado: (2022)

No increased prevalence of autoantibodies neutralizing type I IFNs in idiopathic pulmonary fibrosis patients
por: Philippot, Quentin, et al.
Publicado: (2023)

Evaluation of interleukin-6 and its soluble receptor components sIL-6R and sgp130 as markers of inflammation in inflammatory bowel diseases
por: Nikolaus, Susanna, et al.
Publicado: (2018)

IL-10 Production Is Critical for Sustaining the Expansion of CD5(+) B and NKT Cells and Restraining Autoantibody Production in Congenic Lupus-Prone Mice
por: Baglaenko, Yuriy, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_oibpihrlid2gg40pahgmtp2q8d